|
|
|
| home > ict > Spring 2009 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. ICT provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of ICT. |
 |
| |
|
|
|
| The effects of the recession and the prospect of thinning pipelines are major concerns for pharmaceutical companies; Sriram V of Frost & Sullivan discusses the long-term outlook for CROs. |
|
|
| Nicola Murgatroyd at Phlexglobal examines the importance of the role of clinical research associate and looks at the reasons why the industry is facing a shortage of candidates. |
|
|
| The increasing number of clinical trials being performed in developing economies has made high quality translation more important than ever, argues Mimi Maeda-Nye of TJC Global. |
|
|
|
| James Trammel at i3 Statprobe underlines the value of adaptive randomisation, explaining the methods that can be used to guarantee the validity of statistical conclusions. |
|
|
| In the context of the dramatic increase in the number of late-phase clinical trials worldwide, Kate Trainor of PAREXEL International looks at how the right technology can make a major difference in Phases IIIb and IV. |
|
|
| Tim Davis of Exco InTouch reflects on the immense popularity of SMS communication, and explains how text messaging technology can increase recruitment, retention and compliance in clinical trials |
|
|
| A well-integrated laboratory information management system, with the flexibility to work with an adaptive trial design, greatly increases the ability to get specimen handling, testing and reporting 'right first time', says Ed Krasovec of Starlims. |
|
|
|
|
| For clinical research conducted in developing countries, ethical concerns are a particularly salient issue. Harald Schmidt of the Nuffield Council of Bioethics and Peter G Smith of the London School of Hygiene & Tropical Medicine review the 2008 Declaration of Helsinki. |
|
|
|
| In light of the tough economic times, Richard N Williams of INC Research looks at how value can be maximised and drug development accelerated by embracing fresh regulatory initiatives. |
|
|
|
Beata Paluchowska of Omnicare Clinical Research describes how the challenges involved in clinical trials for cancer drugs can be overcome by means of collaboration with oncology communities and experts from different fields. |
|
|
| Jan Vertommon at Capsugel explains how enhanced bioavailability can improve the quality of data obtained from first-in-human clinical trials and evaluates the ways in which this can be achieved. |
|
|
| Nick Charles of Mayo Clinic presents a case study on the benefits of running a collaborative trial for Graves' ophthalmopathy. |
|
|
|
|
| Jeffrey Litwin of ERT Inc looks at the critical role of central core labs in performing thorough ECG analysis. |
|
|
| Nick Townsend of LabWare explains why configurable LIMS with purpose-built modules are an asset for clinical trials, and looks at the options available when choosing a LIMS product. |
|
|
| As the focus of clinical trial activity shifts towards Asia, Robert Scott-Edwards of ICON Central Laboratories investigates the opportunities and challenges in India. |
|
|
| Geraint Thomas at Laminar Medica outlines the factors to consider when developing a passives cooling system which offers protection while meeting all relevant laws, regulations and guidelines. |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio
BioIVT,
a leading provider of research models and services for drug development, today
announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and
its comprehensive portfolio of transporter assays, multi-transporter models,
transporter systems biology, and molecular transport research solutions.
More info >> |
|
 |
White Papers |
 |
|
Translating Cancer Genomics Into A Personalised Approach For Cancer Patients
PRA Health Sciences (PRA)
Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >> |
|
 |
Industry Events |
 |
Clinical Trial Supply Southeast 2018
2-3 October 2018, Cary, North Carolina
Clinical
Trial Supply Southeast will return to Cary, North Carolina for fall 2018. Part
of our global series of events, this show will attract the leading biotech and
pharma companies from the Southeast region, the event will focus on how
companies can adapt their supply chains to fit into the highly regulated world.
More info >> |
|
|
